UnitedHealth Group ($UNH) stock has fallen over 50% from its 2024 high following reports of a Department of Justice criminal investigation into Medicare Advantage billing fraud. CFRA Research downgraded its 12-month outlook to Sell, citing mounting regulatory risks, margin compression, and lowered EPS guidance.
This in-depth equity research report from CFRA Senior Equity Analyst Paige Meyer breaks down the events driving this historic downturn—and what institutional investors should watch next.
Whether you're a wealth manager, portfolio strategist, or institutional allocator, this report will give you actionable insight into the headwinds UNH faces in 2025, including:
- Heightened Medicare Advantage utilization
- Medicaid reimbursement risk
- DOJ criminal and civil probes
- Market share and margin erosion across Optum
Stay informed with an independent, comprehensive breakdown of UNH's fundamentals, valuation, and future scenarios.
What Is Included In This Report
- Why CFRA believes $UNH is a Sell despite its historical strength
- Key risks from the DOJ’s criminal investigation into Medicare Advantage billing
- How EPS estimates for 2025 were revised downward and what it signals
- Impact of medical cost inflation and care activity on margins
- Why CFRA’s 12-month price target was slashed to $216—well below current trading levels
- Comparative peer analysis and sub-industry outlook for managed care firms
Get instant access to CFRA’s latest research on UnitedHealth Group and find out why institutional analysts are hitting the brakes.
